Alife

Executive Summary

Alife is a San Francisco-based biotechnology company that leverages artificial intelligence to enhance in vitro fertilization (IVF) outcomes. Its configurable software platform integrates with clinic EMR systems to deliver data-driven tools for embryo grading, lab scheduling, and patient communication. By providing actionable insights from clinical data, Alife aims to empower fertility clinics to improve operational efficiency and increase patient success rates. The company was founded in 2018 and is privately held, targeting the growing fertility treatment market with AI-driven solutions. Alife addresses critical challenges in IVF, including subjective embryo assessment and inefficient clinic workflows. Its AI models analyze embryo images and historical outcomes to standardize grading, reducing variability and improving selection accuracy. Additionally, predictive algorithms optimize cycle planning and resource allocation, potentially lowering costs and shortening time-to-pregnancy. As fertility rates decline and demand for assisted reproduction rises, Alife's technology could become a key enabler for clinics seeking competitive advantages. The company's progress is tracked by its integration adoption and clinical validation studies, positioning it for potential scale-up and partnerships.

Upcoming Catalysts (preview)

• Q4 2026FDA Clearance for AI Embryo Grading Software60% success
• Q2 2026Strategic Partnership with Large IVF Clinic Network75% success
• Q3 2026Series B Funding Round Close80% success